---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-134749"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2024-12-10T23:59:59+00:00"
generated_at: "2026-05-29T05:02:56.126761+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology announces Phase 2 CRDF-004 data: 64% ORR in 30mg onvansertib arm vs 33% control

## Summary
- 30mg onvansertib+SoC 64% ORR (7/11) vs 33% (3/9) control; 20mg arm 50% ORR (5/10).
- Onvansertib well-tolerated; no major or unexpected toxicities at either dose.
- Additional CRDF-004 clinical data expected in 1H 2025.
- Conference call held Dec 10, 2024 at 8:00 AM ET.

## SEC filing metadata
- accession: 0000950170-24-134749
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2024-12-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000095017024134749/0000950170-24-134749-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000095017024134749/crdf-20241210.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-134749
- JSON: https://secwatch.observer/filing/0000950170-24-134749.json
- Plain text: https://secwatch.observer/filing/0000950170-24-134749.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.